Catheter-based atrial appendage closure-current data and future developments

• Published in: Der Internist (Berlin) Vol. 59; no. 10; pp. 1028 - 1040
• Main Authors: Skurk, C, Hartung, J J, Leistner, D M, Landmesser, U
• Format: Journal Article
• Language: German
• Published: Germany 01.10.2018
• Subjects: Administration, Oral; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Germany; Humans; Stroke; Germany; Anticoagulants; Stroke prevention; Vitamin K antagonists; Hemorrhage; Atrial fibrillation
• ISSN: 1432-1289
• DOI: 10.1007/s00108-018-0483-5

In Germany more than 1.6 million patients suffer from atrial fibrillation (AF). Within the next decades this number will substantially increase due to current demographic trends with the increasing average age of the population. When untreated, patients with atrial fibrillation have a five times higher risk for stroke as compared with a control cohort. A potent stroke prevention therapy reducing the risk of stroke by approximately 70-80% is primarily treatment with new oral anticoagulants (NOACs). The risk scores for stroke (CHA DS -VASc) and major bleeding (HAS-BLED) in patients with atrial fibrillation share common variables, so that patients with the highest stroke risk often carry a very high bleeding risk. A significant number of patients (ca. 20-30%) are, however, not eligible for long-term anticoagulation, e.g. because of a high bleeding risk. For this population there is an urgent need for alternative stroke prevention strategies, such as catheter-based percutaneous left atrial appendage closure. Current data about the efficiency and safety of this treatment as well as a discussion of ongoing recruitment for randomized studies are discussed in this review.